iFR

Webinar SOLACI | Temas de Actualidad en Hemodinamia

Webinar SOLACI | Up-To-Date-Topics on Hemodynamics

Watch again our Webinar on “Up-To-Date-Topics on Hemodynamics” on our Youtube account.  We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

SOLACI PERIPHERAL | 2nd Clinical Case: Juxtarenal Abdominal Aortic Aneurysm

SOLACI’s Department of Peripheral Endovascular Interventions brings a new challenging clinical case for the whole Latin American medical community so as to continue fostering and sharing scientific knowledge and experience among peers. Tell us what you think about this case and its resolution using the comments section in this post, and answer the questions featured...

Webinar SOLACI - 11/07 - Alternativas de Procedimientos en las Salas de Hemodinamia

Webinar SOLACI | Procedures Options in the Cath Lab

Watch again our Webinar on “Procedures Options in the Cath Lab” on our Youtube account.    We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

iFR en lesiones no culpables: el momento de la medición parece cambiar la historia

Differences in Plaque Progression Depending on its Characteristics

The pattern of growth for each plaque differs according to the presence of certain risk factors. Atheroma volume at baseline was the most important predictor of plaque developing into obstructive lesions, as opposed to other characteristics historically considered as “dangerous.” The aim of this study was to analyze whether the pattern of non-obstructive lesion progression...

EuroPCR 2020 | FABOLUS FASTER: buscando la inhibición plaquetaria más potente y rápida

EuroPCR 2020 | FABOLUS FASTER: In the Quest for the Fastest, Most Potent Platelet Inhibition

This small study tested the pharmacodynamic effects of several antiplatelet agents. It concluded that tirofiban (Aggrastat) provides “more potent and consistent” inhibition of platelet aggregation compared with cangrelor in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. Thirty minutes after the initiation of treatment, there was a nearly threefold difference between tirofiban and cangrelor...

Top